Go to Health Care Provider version
| Diagnosis | Myeloid Leukemia | Study Status | Open |
| Phase | I |
| Age | 18 Years and older | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | CC-96191 will be administered intravenously on a 28-day Cycle |
| Last Posted Update | 2024-04-09 |
| ClinicalTrials.gov # | NCT04789655 |
International Sponsor
CelgenePrincipal Investigators for Canadian Sites
Princess Margaret Cancer CentreCentres
Study Description
This study will explore the safety, tolerability and efficacy of the biologic CC-96191 in acute myeloid leukemia (AML) that has come back or not responded to previous treatment.
Inclusion Criteria
- Patient must be 18 years or older
- Patient must have AML that has come back (relapsed) or not responded to previous treatment
- Patient must be willing to sign a consent form
- Females and males must practice true abstinence or agree to approved contraceptive methods throughout the study, and during the safety follow-up period.
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.
